| Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results M Dietlein, K Weber, A Gandjour, D Moka, P Theissen, KW Lauterbach, ... European journal of nuclear medicine 27, 1598-1609, 2000 | 200 | 2000 |
| Threshold volumes associated with higher survival in health care: a systematic review A Gandjour, A Bannenberg, KW Lauterbach Medical care 41 (10), 1129-1141, 2003 | 175 | 2003 |
| Costs of dialysis—a regional population-based analysis A Icks, B Haastert, A Gandjour, N Chernyak, W Rathmann, G Giani, ... Nephrology Dialysis Transplantation 25 (5), 1647-1652, 2010 | 111 | 2010 |
| Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany M Dietlein, K Weber, A Gandjour, D Moka, P Theissen, KW Lauterbach, ... European journal of nuclear medicine 27, 1441-1456, 2000 | 100 | 2000 |
| Does prevention save costs?: Considering deferral of the expensive last year of life A Gandjour, KW Lauterbach Journal of Health Economics 24 (4), 715-724, 2005 | 86 | 2005 |
| Clinical and cost‐effectiveness of primary prevention of Type 2 diabetes in a ‘real world’routine healthcare setting: model based on the KORA Survey 2000 A Icks, W Rathmann, B Haastert, A Gandjour, R Holle, J John, G Giani, ... Diabetic Medicine 24 (5), 473-480, 2007 | 67 | 2007 |
| Das Leitlinienmanual ÄZQ AWMF Z ärztl Fortbild Qual sich (ZaeFQ) 95 (Suppl I), 1-84, 2001 | 67* | 2001 |
| Methoden der gesundheitsökonomischen Evaluation in der Versorgungsforschung A Icks, N Chernyak, K Bestehorn, B Brüggenjürgen, J Bruns, O Damm, ... Das Gesundheitswesen 72 (12), 917-933, 2010 | 60* | 2010 |
| Theoretical foundation of patient v. population preferences in calculating QALYs A Gandjour Medical Decision Making 30 (4), E57-E63, 2010 | 59 | 2010 |
| Cost-effectiveness analysis of different screening procedures for type 2 diabetes: the KORA Survey 2000 A Icks, B Haastert, A Gandjour, J John, H Lowel, R Holle, G Giani, ... Diabetes care 27 (9), 2120-2128, 2004 | 58 | 2004 |
| Mutual dependency between capabilities and functionings in Amartya Sen’s capability approach A Gandjour Social Choice and Welfare 31 (2), 345-350, 2008 | 57 | 2008 |
| Diabetische retinopathie und makulopathie HP Hammes, KD Lemmen, C Jochmann, P Wiedemann DMW-Deutsche Medizinische Wochenschrift 131 (20), 1173-1175, 2006 | 55* | 2006 |
| An evidence-based evaluation of quality and efficiency indicators A Gandjour, F Kleinschmit, V Littmann, KW Lauterbach Quality Management in Healthcare 10 (4), 41-52, 2002 | 55 | 2002 |
| Review of quality-of-life evaluations in patients with angina pectoris A Gandjour, KW Lauterbach Pharmacoeconomics 16 (2), 141-152, 1999 | 54 | 1999 |
| Costs of patients with chronic kidney disease in Germany A Gandjour, W Armsen, W Wehmeyer, J Multmeier, U Tschulena PloS one 15 (4), e0231375, 2020 | 49 | 2020 |
| Socioeconomic burden of hip fractures in Germany EJ Weyler, A Gandjour Gesundheitswesen (Bundesverband der Arzte des Offentlichen …, 2007 | 49* | 2007 |
| Budgetary impact and cost drivers of drugs for rare and ultrarare diseases M Schlander, CM Dintsios, A Gandjour Value in Health 21 (5), 525-531, 2018 | 47 | 2018 |
| Direct costs of pediatric diabetes care in Germany and their predictors A Icks, J Rosenbauer, B Haastert, W Rathmann, M Grabert, A Gandjour, ... Experimental and clinical endocrinology & diabetes 112 (06), 302-309, 2004 | 47 | 2004 |
| Utilitarian theories reconsidered: common misconceptions, more recent developments, and health policy implications A Gandjour, KW Lauterbach Health care analysis 11, 229-244, 2003 | 47 | 2003 |
| Future costs in economic evaluation: a comment on Lee TL Feenstra, PHM van Baal, A Gandjour, WBF Brouwer Journal of health economics 27 (6), 1645-1649, 2008 | 41 | 2008 |
